Loading
Seer, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Farokhzad Omid, was filed 24 Aug 2023.
Seer, Inc.: what insiders have been doing
Every trade that managers of Seer, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector and is based in Redwood City, United States. It was founded in 2017. 9 insiders have disclosed 18 filings since 22 October 2025.
The flow runs one way only: 6 sales worth €156k, from 3 insiders, and no purchase. Farokhzad Omid filed the largest sale, €58k, on 21 November 2025.
The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
Compared with its exchange (3,171 companies, median 24 filings), a count of 18 filings is below the norm. Looking back to 2020, when coverage begins, insiders filed 11 purchases and 62 sales. The 10-K for the year ended 31 December 2025 shows 16.6 m USD of revenue and -73.6 m USD of net income.
These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
170
Thresholds
n/a
Buy Volume
€29M
11 ops. · all time
Sell Volume
€128M
62 ops. · all time
Who traded when
BuySaleDavid R. Horn6 sales
Omid Farokhzad5 sales
Dipchand Nishar2 sales
Since the insiders bought
- -35.6%Entry US$2.50 · Close at T+365 US$1.61
- -56.7%Entry US$54.01 · Close at T+365 US$23.40
- -66.2%Entry US$75.65 · Close at T+365 US$25.56
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Seer, Inc. Strong Buy (bullish), based on 1 analysts. Average price target: US$4.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 23,388 of 26,250 companies
22.8
score / 100
Value4
Quality41
FCF yld-41%
Earn yld-65%
EV/EBITDA·
ROE-26%
Gross mgn50%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$2.03
Analyst consensus
1 analystsStrong buy
US$4.00Target US$4.00(+97%)US$4.00
Income statement
RevenueUS$16.1M
Gross profitUS$8M50% margin
EBITDA-US$71.9M-446% margin
Net income-US$73.6M-456.6% margin
Valuation
PER (forward)-1.9x
P/Book0.5x
Beta1.47
Balance sheet & cash
Market capUS$112.4M
Total debtUS$23.7M
Free Cash Flow-US$46.2M
Debt / Equity10%
Profitability & ownership
ROE-26.4%
ROA-15.3%
% insiders14.8%
% institutions49.2%
Last declaration on 19 August 2026
Declarations170 total
7,309 shares@ US$2.02620.014% mcap1.3% of flowClass A Common StockSEC:0001834217-26-000008:0
16,500 shares0Class A Common StockSEC:0001896292-26-000002:0
16,500 shares0Class A Common StockSEC:0001239757-26-000002:0
16,500 shares0Class A Common StockSEC:0001117003-26-000003:0
16,500 shares0Class A Common StockSEC:0001519500-26-000004:0
12,375 shares0Class A Common StockSEC:0001873463-26-000002:0
16,500 shares0Class A Common StockSEC:0001292341-26-000002:0
10,660 shares@ US$2.18250.022% mcap21.5% of flowClass A Common StockSEC:0001519500-26-000002:0
10,660 shares@ US$2.18250.022% mcap100.0% of flowCommonSEC144:0001950047-26-006953
24,385 shares@ US$1.99495.5% of flowClass A Common StockSEC:0001586852-26-000004:0
7,743 shares@ US$1.99491.3% of flowClass A Common StockSEC:0001834217-26-000004:0
79,000 shares0Class A Common StockSEC:0001834217-26-000002:0
697,162 shares0Class A Common StockSEC:0001586852-26-000002:0
2,117,138 sharesClass A Common StockSEC:0001586852-25-000007:1
1,438,057 sharesClass A Common StockSEC:0001586852-25-000007:0
4,088 sharesClass A Common StockSEC:0001117003-25-000005:0
6,797 shares@ US$1.97141.2% of flowClass A Common StockSEC:0001834217-25-000005:0
33,838 shares@ US$1.97147.8% of flowClass A Common StockSEC:0001586852-25-000004:0
41,000 shares0Class A Common StockSEC:0001415889-25-023618:0
6,827 shares@ US$2.04411.2% of flowClass A Common StockSEC:0001415889-25-022596:0
33,992 shares@ US$2.04418.0% of flowClass A Common StockSEC:0001415889-25-022594:0
20,500 shares0Class A Common StockSEC:0001415889-25-019575:0
17,083 shares0Class A Common StockSEC:0001415889-25-019577:0
20,500 shares0Class A Common StockSEC:0001415889-25-019573:0
20,500 shares0Class A Common StockSEC:0001415889-25-019571:0
25 of 170 declarations
About Seer, Inc.
Seer, Inc. is a U.S.-based life sciences company listed on the NASDAQ in the United States. For French-speaking investors in France, Belgium, and Switzerland, it is best viewed as a proteomics and biotechnology infrastructure story rather than a traditional therapeutics company. Seer’s core mission is to enable deep, unbiased protein analysis in order to improve understanding of human biology and, ultimately, support research that may lead to better health outcomes. The company was founded in 2017 and was incorporated in Delaware under the name Seer Biosciences, Inc. before adopting the Seer, Inc. name in 2018. Its headquarters and main R&D operations are in Redwood City, California, placing it squarely in the Bay Area biotech ecosystem.
Seer’s business model centers on commercializing research-use-only proteomics tools. Its flagship offering is the Proteograph Product Suite, an integrated platform that combines engineered nanoparticles, consumables, automation instruments, and data-analysis software. The platform is designed to expand the depth and consistency of proteomic workflows, making high-throughput protein analysis more accessible to academic laboratories, biopharma companies, contract research organizations, and other research institutions. In practical terms, Seer is attempting to build a differentiated technology platform in a still-developing market where adoption depends on scientific validation, workflow compatibility, and reproducible data quality.
Read moreShow less
From a competitive standpoint, Seer operates in a specialized segment of the life sciences tools market where barriers to entry include intellectual property, instrument integration, and customer trust. The company positions its technology around deeper proteomic coverage, reproducibility, and workflow standardization. Its international footprint extends beyond the United States into Europe and other regions through a customer and partner base that includes research organizations and commercial life-science users. Seer also supports customer engagement through a Technology Access Center model, including facilities in Redwood City and Bonn, Germany, which help demonstrate the platform and support user adoption.
Recent developments underline that Seer remains in an execution phase. In February 2026, the company reported full-year 2025 results showing revenue of approximately $16.6 million and provided 2026 revenue guidance in the $16 million to $18 million range, reinforcing the view that the business is still at an early commercialization stage. The company has also continued to expand its product suite, including higher-throughput iterations of the Proteograph platform, reflecting a strategy focused on broadening use cases and improving scalability. For equity investors, that means SEER remains a high-risk, innovation-driven NASDAQ name where adoption momentum, product differentiation, and cash discipline are likely to matter more than near-term profitability. SEC Form 4 insider transactions should therefore be interpreted as one data point within a broader narrative of commercialization progress and strategic uncertainty.
